Novel ALK inhibitor NVL-655 has potent preclinical activity against lorlatinib-resistant G1202R compound mutationsHayato Mizuta,Ludovic Bigot,Siro Simizu,Anupong Tangpeerachaikul,Henry E. Pelish,Luc FribouletCANCER SCIENCE(2023)引用 0|浏览8暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要